| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Non-cleavable Linker
Boc-NH-C6-Br does not have a specific biological target as it is a linker used in ADC design. Its role is to serve as a non-cleavable connector between an antibody and a payload in ADC synthesis. The bromine atom provides a reactive handle for conjugation to various functional groups, while the Boc group protects the amine during synthesis. |
|---|---|
| ln Vitro |
In vitro activity of Boc-NH-C6-Br is demonstrated by its ability to serve as a non-cleavable linker for ADC synthesis. The compound's utility is in enabling the conjugation of drugs or payloads to antibodies for targeted cancer therapy. Its non-cleavable nature provides stable conjugation for ADC applications, ensuring that the payload remains attached to the antibody until the ADC is internalized by target cells.
|
| ln Vivo |
In vivo activity of Boc-NH-C6-Br is observed in the context of ADCs synthesized using this linker. These ADCs demonstrate targeted antitumor efficacy in animal models by delivering cytotoxic payloads specifically to tumor cells. The non-cleavable linker provides stable conjugation, preventing premature payload release in circulation.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays are not typically performed for Boc-NH-C6-Br as it is a linker, not a pharmacologically active compound. Its characterization involves assessing its reactivity with nucleophiles and its ability to form stable conjugates with antibodies and payloads. Purity and identity are confirmed using HPLC, NMR, and mass spectrometry.
|
| Cell Assay |
In vitro cellular assays for Boc-NH-C6-Br are conducted using ADCs synthesized with this linker. These assays evaluate the cytotoxicity of the resulting ADCs against target cancer cell lines. Cell viability is assessed using MTT or other assays, and IC50 values are determined to evaluate the potency of the ADC.
|
| Animal Protocol |
In vivo animal experiments for Boc-NH-C6-Br involve administering ADCs synthesized with this linker to tumor-bearing mouse models. Efficacy is evaluated by measuring tumor growth inhibition, survival rates, and body weight changes. The linker's performance is assessed based on the ADC's pharmacokinetic profile, stability, and antitumor activity.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Boc-NH-C6-Br are typically derived from studies of ADCs synthesized using this linker. The non-cleavable linker influences the ADC's stability in circulation and its pharmacokinetic profile. The compound has a molecular weight of 280.2 and is soluble in DMSO at 40 mg/mL (142.76 mM). It should be stored at -20°C.
|
| Toxicity/Toxicokinetics |
Toxicological data for Boc-NH-C6-Br are typically derived from studies of ADCs synthesized using this linker. The non-cleavable linker is designed to provide stable conjugation and minimize premature payload release. The compound is for research use only. Standard laboratory safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
Boc-NH-C6-Br (CAS#: 142356-33-0) has the molecular formula C11H22BrNO2 and a molecular weight of 280.2. Its SMILES is C(NCCCCCCBr)(OC(C)(C)C)=O. The compound is a non-cleavable ADC linker used for antibody conjugation in ADC synthesis and PROTAC linker applications. Purity is ≥97%. It is for research use only.
|
| Molecular Formula |
C11H22BRNO2
|
|---|---|
| Molecular Weight |
280.20
|
| Exact Mass |
279.083
|
| CAS # |
142356-33-0
|
| PubChem CID |
16211353
|
| Appearance |
Colorless to off-white solid-liquid Mixture
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
340.1±25.0 °C at 760 mmHg
|
| Flash Point |
159.5±23.2 °C
|
| Vapour Pressure |
0.0±0.7 mmHg at 25°C
|
| Index of Refraction |
1.473
|
| LogP |
3.63
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
15
|
| Complexity |
178
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
BrC([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=O)OC(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H]
|
| InChi Key |
NXQXVXILNVTMNA-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C11H22BrNO2/c1-11(2,3)15-10(14)13-9-7-5-4-6-8-12/h4-9H2,1-3H3,(H,13,14)
|
| Chemical Name |
tert-butyl N-(6-bromohexyl)carbamate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 40 mg/mL (142.76 mM)
H2O : 1 mg/mL (3.57 mM) |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5689 mL | 17.8444 mL | 35.6888 mL | |
| 5 mM | 0.7138 mL | 3.5689 mL | 7.1378 mL | |
| 10 mM | 0.3569 mL | 1.7844 mL | 3.5689 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
